What is the ROE (Return on Equity) of Verastem this year?
The ROE of Verastem this year is -1.11 undefined.
Verastem ROE 2024
Verastem ROE
-1.11
Ticker
VSTM
ISIN
US92337C1045
WKN
A1JTPU
In 2024, Verastem's return on equity (ROE) was -1.11, a -28.56% increase from the -1.56 ROE in the previous year.
Verastem Aktienanalyse
What does Verastem do?
Verastem Inc. is a biopharmaceutical company founded by Dr. Christoph Westphal in Cambridge, Massachusetts, in 2010. The company focuses on developing drugs for the treatment of cancer and other serious diseases using technologies based on small molecules and RNA interference. The company specializes in developing therapies for patients with particularly aggressive types of cancer, such as diffuse large B-cell lymphoma (DLBCL), mesothelial tumors, liver cancer, and pancreatic cancer. Verastem collaborates closely with leading academic research institutions and clinics around the world to test and validate the efficacy and safety of its therapies. Verastem's business model is based on identifying and developing drug candidates based on the needs of patients with serious diseases. The company uses patented screening technologies to identify compounds that selectively target specific cancer cells without harming healthy cells. These compounds are then tested in preclinical and clinical studies to demonstrate their efficacy and safety for use in humans. One of Verastem's main areas of focus is the development of drugs that target signaling pathways in cancer cells. The company has several drugs in its pipeline that aim to inhibit proteins that are central to the growth and survival of cancer cells. These include VS-6063, VS-5584, and VS-5095. VS-6063 is a small molecule that targets the inhibition of the Focal Adhesion Kinase (FAK) protein. FAK plays a key role in the development and progression of cancer by promoting the growth and movement of cancer cells. VS-6063 is currently being studied in clinical trials for the treatment of mesothelioma, pancreatic cancer, and other types of cancer. VS-5584 is a small molecule that targets the inhibition of the mammalian Target of Rapamycin (mTOR) protein. mTOR is an important regulator of cell growth and division that is overactive in many types of cancer. VS-5584 is currently being studied in clinical trials for the treatment of liver cancer and other types of cancer. VS-5095 is a small molecule that targets the inhibition of the Wnt protein, which plays a crucial role in regulating cell proliferation and differentiation. Wnt is also involved in the development of cancer as it can contribute to the transformation of normal cells into cancer cells. VS-5095 is currently in preclinical studies for the treatment of various types of cancer. Verastem also has a promising pipeline of RNA interference therapies that aim to inhibit the expression of specific genes in cancer cells. One such therapy currently in clinical testing, VS-6061, targets the inhibition of the KRAS gene, which is mutated in many types of cancer and can promote the survival and growth of cancer cells. Overall, Verastem aims to develop drugs that are better tailored to the individual needs of patients and help them fight their disease. With its innovative research approach and strong pipeline of drug candidates, the company has the potential to fundamentally change the way cancer is treated. Verastem ist eines der beliebtesten Unternehmen auf Eulerpool.com.ROE Details
Decoding Verastem's Return on Equity (ROE)
Verastem's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.
Year-to-Year Comparison
Analyzing Verastem's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.
Impact on Investments
Verastem's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.
Interpreting ROE Fluctuations
Changes in Verastem’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.
Frequently Asked Questions about Verastem stock
How has the Return on Equity (ROE) of Verastem developed compared to the previous year?
The ROE of Verastem has increased by -28.56% decreased compared to the previous year.
What impact does a high ROE (Return on Equity) have on investors of Verastem?
A high ROE indicates that Verastem generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.
What impact does a low ROE (Return on Equity) have on investors of Verastem?
A low ROE can indicate that Verastem is having difficulties monetizing its investments successfully and can be a negative signal for investors.
How does a change in the ROE (Return on Equity) of Verastem affect the company?
A change in ROE (Return on Equity) of Verastem can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.
How to calculate the ROE (Return on Equity) of Verastem?
The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.
Which factors influence the ROE (Return on Equity) of Verastem?
Some factors that can influence Verastem's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.
What strategic measures can take to improve the ROE (Return on Equity)?
To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.
How much dividend does Verastem pay?
Over the past 12 months, Verastem paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Verastem is expected to pay a dividend of 0 USD.
What is the dividend yield of Verastem?
The current dividend yield of Verastem is .
When does Verastem pay dividends?
Verastem pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Verastem?
Verastem paid dividends every year for the past 0 years.
What is the dividend of Verastem?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Verastem located?
Verastem is assigned to the 'Health' sector.
Wann musste ich die Aktien von Verastem kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Verastem from 10/6/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/6/2024.
When did Verastem pay the last dividend?
The last dividend was paid out on 10/6/2024.
What was the dividend of Verastem in the year 2023?
In the year 2023, Verastem distributed 0 USD as dividends.
In which currency does Verastem pay out the dividend?
The dividends of Verastem are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Verastem
Our stock analysis for Verastem Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Verastem Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
